Compare JOE & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | TNGX |
|---|---|---|
| Founded | 1936 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.1B |
| IPO Year | 2002 | 2020 |
| Metric | JOE | TNGX |
|---|---|---|
| Price | $67.74 | $23.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $44.88 |
| AVG Volume (30 Days) | 171.0K | ★ 3.5M |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 56.69 | 26.89 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $513,246,000.00 | $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.57 | N/A |
| P/E Ratio | $73.35 | ★ N/A |
| Revenue Growth | 27.44 | ★ 48.29 |
| 52 Week Low | $48.82 | $7.12 |
| 52 Week High | $73.54 | $34.39 |
| Indicator | JOE | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 47.72 |
| Support Level | $66.12 | $20.46 |
| Resistance Level | $71.86 | $25.68 |
| Average True Range (ATR) | 1.49 | 1.78 |
| MACD | 0.28 | 0.35 |
| Stochastic Oscillator | 66.32 | 33.57 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.